DocumentsDate added
International Journal of Risk & Safety in Medicine 22 (2010) 89-92.
Peter R. Breggin
Abstract: Electroconvulsive therapy (ECT) and the machines that deliver it have never been tested for safety and efficacy in order to receive approval from the FDA. The American Psychiatric Association and ECT advocates protested when the FDA took steps to classify the machines as posing “an unreasonable risk of illness or injury”, which would have required their testing before approval. Without requiring this testing, the FDA is now preparing to classify the treatment and the machines as safe. This article reviews evidence demonstrating that ECT is very harmful to the brain and mind, and concludes that the FDA should demand the usual testing, starting with animals, that is required before psychiatric treatments and machines are approved for marketing and use.
"Exposure to SSRI Antidepressants In Utero Causes Birth Defects, Neonatal Withdrawal Symptoms, and Brain Damage." Ethical Human Psychology and Psychiatry, 10, 5-9, 2008.
"Practicle Applications: 22 Guidelines for Counseling and Psychotherapy." Ethical Human Psychology and Psychiatry, 10, 43-57, 2008.
"ECT Damages the Brain: Disturbing News for Patients and Shock Doctors Alike." Ethical Human Psychology and Psychiatry, 9, 83-86, 2007.
"Intoxication Anosognosia: The Spellbinding Effect of Psychiatric Drugs", Ethical Human Psychology and Psychiatry, 8, 201-215, 2006.
"Drug Company Suppressed Data on Paroxetine-Induced Stimulation: Implications for Violence and Suicide", Ethical Human Psychology and Psychiatry, 8, 255-263, 2006.
"How GlaxoSmithKline Suppressed Data on Paxil-Induced Akathisia: Implications for Suicidality and Violence", Ethical Human Psychology and Psychiatry, 8, 91-100, 2006.
"Court Filing Makes Public My Previously Suppressed Analysis of Paxil's Effects." Ethical Human Psychology and Psychiatry, 8, 77-84, 2006.
"Politics, Practice, and Breaking News." Ethical Human Psychology and Psychiatry, 8, 3-6, 2006.
"Recent regulatory changes in antidepressant labels: Implications for activation (stimulation) in clinical practice." Primary Psychiatry, 13, 57-60, 2006.